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ABSTRACT 
Objective: In the present work, rapid and sensitive isocratic RP-UPLC method was established and comprehensive validation study for the 
estimation of Tolperisone HCl and Paracetamol was carried out according to international conference on harmonization (ICH) guidelines.  
Methods: Simultaneous estimation was chromatographed using 0.1% o-phosphoric acid in water and acetonitrile (70: 30 v/v) as a mobile phase at 
a flow rate of 0.20 ml/min with 35 ºC column temperature. Chromatographic separation accomplished isocratically on Acquity UPLC BEH C18 (50 
mm ×2.1 mm, particle size 1.7 µm) and detection utilizing photodiode array detector at 254 nm. Injection volume was 2.0 µl.  
Results: The calibration curve was linear over the wide concentration range of 6.0µg/ml to 54.0µg/ml and 20.0µg/ml to 180.0µg/ml for 
Tolperisone HCl and Paracetamol, respectively. The retention time of Tolperisone HCl and Paracetamol was 1.396 and 2.625 min, respectively and 
the total analysis time was 5.0 min. Based on the results, the validated method was effectively applied for the estimation of Tolperisone HCl and 
Paracetamol in combined dosage form and in single pharmaceutical formulations with a new generation instrument, ultra performance liquid 
chromatography (UPLC). Moreover, the method helps to get better quality control and to pledge therapeutic efficacy.  
Conclusion: The method is simple, less time consuming and comparatively cost effective than existing methods.  
Keywords: Simultaneous, Isocratic, Stability indicating, Ultra performance liquid chromatography, Tolperisone HCl, Paracetamol. 
 
INTRODUCTION  
Tolperisone HCl, 2-methyl-1-(4-methylphenyl)-3-(1-piperidyl) 
propan-1-one is a piperidine derivative. The drug acting as a muscle 
relaxant for spastic paralysis and another encephalopathy are 
manifested with muscular dystopia and other muscle related 
pathological problem caused by neurological diseases [1]. 
Paracetamol, N-(4-hydroxyphenyl) ethanamide acting as a mild 
analgesic as well as an antipyretic agent to reduce fever and pain, 
Paracetamol is an active metabolite of Phenacetin [2]. The chemical 
structures are given in fig. 1. 
 
 
Fig. 1: Chemical structure of (a) Paracetamol (b) Tolperisone HCl 
According to the review of the literature, there are many methods 
available for the estimation of Tolperisone HCl or Paracetamol either 
in single or combination pharmaceutical dosage form or in bulk drug 
by HPLC and HPTLC [3-5]. Some analytical methods are reported for 
the analysis of both the drugs from different sample matrix in single 
dosage form or bulk [6-9]. A spectrometric method for the 
simultaneous quantitative analysis of Tolperisone HCl and 
Paracetamol in the tablet has been reported [10, 11]. There is no any 
method reported for the simultaneous determination of Tolperisone 
HCl and Paracetamol by UPLC. The objective of this work was to 
develop a simple, buffer free, rapid and robust stability indicating 
assay method. The content uniformity study was carried out to show 
the applicability of the method for the drug product. All the 
validation parameter performed as per ICH Q2 (R1) guideline [12]. 
MATERIALS AND METHODS 
Reagents and chemicals 
The Tolperisone HCl and Paracetamol reference standards were 
gifted by Hetero labs limited, Visakhapatnam, India. The 
commercially available combination and individual pharmaceutical 
formulations labeled 150 mg Tolperisone HCl and 500 mg 
Paracetamol content were purchased from the market. HPLC grade 
acetonitrile and o-phosphoric acid purchased from Merck India 
Limited (Mumbai, India). High purity water was prepared using 
Milli-Q, Millipore (Milford, USA) water purification system. The 
other chemicals like hydrochloric acid, sodium hydroxide pellets and 
hydrogen peroxide solution 30% (v/v) were analytical grade, 
purchased from Ranbaxy Fine Chemicals (New Delhi, India) and 0.45 
μm and 0.22μm membrane filters were obtained from Pall Life 
Sciences (Mumbai, India). 
Equipment 
The Waters AcquityTM UPLC chromatographic system used to 
perform development and validation (Waters, Milford, MA, USA). 
This system consists of a binary solvent manager (BMS), the 
photodiode array detector, sample manager (SM) and column oven 
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connected to a multi-instrument data acquisition and processing 
system Empower 2.1 version. A Sartorius CPA2P analytical 
microbalance (Gottingen, Germany), an ultrasonic bath SONICA used 
for degassing purpose from Spincotech Pvt. Ltd. (Mumbai, India). 
Milli-Q, Elix-3 water purification system (Millipore, Milford, USA) 
used as a HPLC grade water source. 
Chromatographic condition 
Chromatographic analysis was performed on waters Acquity BEH C18, 
50 mm x2.1 mm and 1.7 µm columns. The mobile phase consisted 
mixture of 0.1% ortho-phosphoric acid in water: acetonitrile (70:30 
v/v) the mixture was degassed in an ultrasonic bath. The flow rate of 
the mobile phase was adjusted at 0.20 ml/min and the injection 
volume was 2.0 µl. Elution was monitored using PDA detector at a 
wavelength of 254 nm at a column temperature 35 °C. 
Stock solutions for Standard  
The stock solution for the standard was prepared from the reference 
standard to furnish the final concentration of Tolperisone HCl 150 µg/ml 
and Paracetamol 500µg/ml for standard stock solutions preparation. 
Stock solutions for test 
The stock solution for the sample was prepared from 
Pharmaceutical formulation (twenty combination tablets were 
crushed and powdered) to obtain a final concentration of 
Tolperisone HCl 150µg/ml and Paracetamol 500µg/ml (equivalent 
weight) for test stock solutions preparation.  
Standard and test solution 
Standard and test solutions were prepared (30µg/ml of Tolperisone 
HCl solution and 100µg/ml of Paracetamol) from respective stock 
solution by taking 5 ml stock solution in 25 ml volumetric flask and 
dilute with mobile phase up to 25 ml. 
RESULTS  
Method development and optimization 
A selection of the method depends upon the nature of the sample, 
solubility, and molecular weight. Tolperisone HCl and Paracetamol 
can be easily soluble in water acetonitrile. Column and mobile phase 
selection made to avoid the all inexcusable aspects like high column 
backpressure, a poor resolution between two peaks, less theoretical 
plates, peak tailing and shape.  
The Paracetamol and Tolperisone HCl were eluting at all most same 
retention time, using different column chemistry as well as column 
length like HSS T3 (1.8 µm particle size), BEH C 8 (1.7 µm particle 
size), BEH Shield RP 18 (1.7 µm particle size) with different mobile 
phase combinations such as 0.02M phosphate buffer, 0.02M acetate 
buffer with acetonitrile and methanol. The result was found 
satisfactory with 0.1% o-phosphoric acid in water: acetonitrile as an 
isocratic elution. Method optimization made with different mobile 
phase composition starts from 50:50 to 70:30, 0.1% OPA in water: 
acetonitrile (table 1). The satisfactory results found with 70:30 
ratios, at 35 °C temperature with adopted all chromatographic 
condition. 
 
Table 1: Summary of mobile phase optimization 
Mobile Phase-A Mobile Phase-B Observation from chromatogram 
Water Methanol Very broad peaks with peak splitting and less resolved peaks 
Water Acetonitrile Broad, less resolved peaks with tailing 
5 mM Ammonium acetate Methanol Merged peaks, very broad and symmetry factor is not satisfactory 
5 mM Ammonium acetate Acetonitrile Broad, less resolved peaks 
5 mM Potassium dihydrogen phosphate(pH= 2.5 by OPA) Methanol Peak eluted early with peak tailing, Poor resolution. 
0.1% o-phosphoric acid in water Methanol Peaks are broad but resolved 
0.1% o-phosphoric acid in water Acetonitrile Good, sharp peak shape with good System Suitability results. 
 
The standard solution was screened over the range 190-400 nm by use of photodiode array detector. On the basis of peak absorption maxima of the 
analyte and the degradation products, the 254 nm was decided as the detection wavelength. This gives the maximum chromatographic 
compatibility to the method. The chromatographs of standard preparation (a) and test preparation (b) are given in fig. 2. 
 
Stress degradation-specificity study 
Forced degradation studies were carried out for the applicability of 
the method as a stability-indicating method for the estimation of 
Tolperisone HCl and Paracetamol. The study was performed on 
Tolperisone HCl and Paracetamol by applying stress conditions like 
exposure of daylight (72h), acid and alkali hydrolysis (1 N HCl and 
NaOH), oxidation (3% H2O2) and heat (60 oC, 72h). Acid, alkali at 
40oC and oxidation degradation was carried out at room 
temperature for 2h in a water bath. The peak purity of the principal 
peaks of the chromatogram of Tolperisone HCl and Paracetamol 
(combination tablet) degradation sample was checked with the help 
of a PDA detector.  
The peaks of degradation products could be observed from the 
chromatographs of oxidation and acidic stress conditions given in 
fig. 3(a) and (b) respectively. The outcome of the study shows 
degradation under all stress condition in more or less percent (table 
2). The principle peaks were observed pure and well resolved from 
degradation product, that confirmed by PDA peak purity spectrum. 
The result indicates that proposed method is specific and stability 
indicating. 
Validation parameters 
Method validation characteristics deal with solution stability study, 
system suitability, linearity, limit of quantification, limit of detection, 
accuracy, precision and robustness.  
The method for the simultaneous estimation of Tolperisone HCl and 
Paracetamol was validated as per ICH guidelines.  
Solution stability 
Solution stability period for the solutions of the standard 
preparation and test preparation was evaluated. The solutions were 
stored at 3-5 °C and ambient temperature without protection 
against light and tested at the interval of 6, 12, 24, 36 and 48h. The 
responses for the aged solution were evaluated using a freshly 
prepared standard solution after each interval.  
The solution stability was evaluated by the means of retention time, 
area and degradation occurred during the study.  
However, the results show that not much variation in the peak area 
and retention time for test solution against the standard solution 
and no degradation happened during the study. The percentage 
assay for both the drugs was obtained 98.71% to 101.30%. 
Accuracy study 
Accuracy was assessed by the recovery study at three level 50%, 
100% and 150% of sample concentrations, for each level three 
different sets were prepared and injected in duplicate. The % 
recovery was found between 99.46-100.54% and 99.55-100.13% for 
Tolperisone HCl and Paracetamol, respectively. The results are 
under the acceptance criteria to ICH guideline Q2 (A) (table 3). 
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(a) Chromatogram of Paracetamol and Tolperisone HCl reference standard 
 
 
(b) Chromatogram of Paracetamol and Tolperisone HCl combination tablet 
Fig. 2: Chromatographs of standard (a) and test preparation (b) 
 
 
(a) Oxidation stress degradation 
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(c) Alkali stress degradation 
Fig. 3: Chromatographs of stress degradation study 
 
Table 2: Data table for force degradation results 
Name  
of drug 








Tolperisone HCl Standard 489653 15.0 ----- ----- 
Acid 451319 14.9 96.8 3.2 
Alkali 444010 15.2 94.4 5.6 
Oxidation 410119 15.1 92.8 7.2 
Thermal 473921 15.0 89.5 10.5 
Photolytic 456012 14.8 83.2 16.8 
Paracetamol Standard 1941020 50.0 ----- ----- 
Acid 1749104 49.9 95.5 4.5 
Alkali 1700309 50.0 93.1 6.9 
Oxidation 1652913 49.8 90.3 9.7 
Thermal 1853621 50.1 87.6 12.4 
Photolytic 1799822 49.8 85.5 14.5 
a: Mean area of five injections of standard and two injections of sample treated with degradation conditions 
 
Table 3: Accuracy study of Tolperisone HCl and paracetamol 
Drug substance Accuracy level % Prepared concentration (µg/ml)a Observed Concentration 
(µg/ml)a 
Mean recovery (%) RSD  
(%) 
TOL 50% 15.70 15.79 100.54 1.43 
100% 30.12 29.96 99.46 0.59 
150% 44.86 45.04 100.41 1.00 
PAR 50% 50.49 50.50 100.03 1.09 
100% 99.74 99.54 100.13 0.82 
150% 149.02 148.35 99.55 0.25 
a: Mean of three replicates for each accuracy level 
 
Limit of detection and limit of quantification  
The measurement of LOD and LOQ were performed by preparing the 
serial dilution of stock solution until the signal to noise ratios were 
3:1 and 10:1 for Limit of detection and Limit of quantification, 
respectively. LOD for Paracetamol and Tolperisone HCl were 0.2 
µg/ml and 0.06 µg/ml and LOQ values were 0.5µg/ml and 0.15 
µg/ml, respectively.  
Linearity study 
The peak area of Tolperisone HCl and Paracetamol showed linear 
calibration curve with respect to concentrations over the range of 6-
54µg/ml and 20-180µg/ml for Tolperisone HCl and Paracetamol 
respectively. The linear regression equations were y = 96814x-88376, 
correlation coefficient 0.9999 for Tolperisone HCl and y = 47275x-
47746, correlation coefficient 0.9998 for Paracetamol, where x is the 
concentration in µg/ml and y is the peak absorbance in units. The 
result showed an excellent correlation exists between the peak area 
and concentration of the drugs solution within the selected wide range 
of concentration, indicated previously. The “Linear Regression Least 
Squares Fit” was the data analysis tool for linearity.  
Precision study 
The precision study was carried out in terms of method precision and 
intermediate precision. Method precision was assessed by analyzing 
three times, multiple preparations of the same drug sample. Six 
different sample sets were injected to evaluate method precision on 
the same day.  
Moreover, freshly prepared sample solutions were analyzed on 
each of two successive days for intermediate precision study. The 
% assay values calculated against peak area of the standard 
solution for drug samples. The content uniformity test also 
performed for different ten sets and % RSD calculated for both 
study were well within the acceptance criteria, less than 2% RSD 
of peak area. 
Robustness study 
In robustness study, influences of different (k) chromatographic 
parameters were evaluated by assaying test solution after small but 
deliberate changes in the analytical conditions. The factor examined 
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temperature, detection wavelength, column lot and flow rate. There 
was no significance influence observed on retention time and % 
assay during this study, which suggests that method, is highly 
robust. The results are given in (table 4). 
 
Table 4: Summary data of robustness study of Tolperisone HCl and Paracetamol 
Robustness Conditions % Assaya RTb 
(min) 
% RSDd  
of STD 
System Suitability Parameters 
Theoretical  Platese USP Tailinge 
Summary of paracetamol 
Flow rate 0.18 ml/min 100.82 1.407 0.54 6655 1.137 
Flow rate 0.22 ml/min 101.06 1.212 0.47 6475 1.140 
0.1% OPA: acetonitrile (68:32) 100.62 1.312 0.56 6525 1.135 
0.1% OPA: acetonitrile (72:28) 102.00 1.360 1.22 6550 1.137 
Column temperature 28 ° C 99.97 1.332 1.08 6545 1.137 
Column temperature 32 ° C 101.34 1.326 0.47 6522 1.136 
Detection wavelength 251 nm 99.15 1.329 0.96 6534 1.136 
Detection wavelength 257 nm 101.39 1.329 0.45 6535 1.137 
Summary of tolperisone HCl 
Flow rate 0.18 ml/min 99.96 2.636 0.47 2708 1.136 
Flow rate 0.22 ml/min 99.95 2.274 0.78 2598 1.137 
0.1% OPA: acetonitrile (68:32) 99.41 2.856 1.02 2678 1.134 
0.1% OPA: acetonitrile (72:28) 99.94 2.847 1.12 2657 1.136 
Column temperature 28 °C 99.94 2.479 0.43 2631 1.135 
Column temperature 32 °C 101.45 2.451 0.35 2611 1.134 
Detection wavelength 251 nm 98.39 2.463 0.41 2621 1.135 
Detection wavelength 257 nm 101.41 2.462 0.83 2618 1.135 
a: Mean of % assay of five replicate, b: Mean retention time of five replicate injections, c: Mean of the percentage relative standard deviation of 
standard sample, d: Mean theoretical plates and USP tailing factor obtain from five replicate samples 
 
System suitability studies  
The standard solution of 100µg/ml of Tolperisone HCl solution and 
30µg/ml of Paracetamol was prepared and injected before all 
validation parameter. System suitability parameters like theoretical 
plates, peak asymmetry, resolution, % RSD for peak area and 
retention time were calculated from the chromatogram of standard 
solution (table 5). 
 

























Validation parameters Paracetamol Tolperisone HCl 
Solution stability 0.02 6676 1.136 0.47 2669 1.134 
Specificity 0.69 6679 1.136 0.23 2659 1.134 
Linearity 0.52 6681 1.137 0.83 2657 1.135 
LOQd 0.18 6672 1.136 0.98 2662 1.136 
Method precision 0.45 6671 1.137 0.44 2661 1.135 
Interf. precision 0.18 6675 1.136 0.25 2667 1.134 
Accuracy 0.89 6684 1.136 0.85 2679 1.134 
Robustness 0.71 6552 1.137 0.69 2648 1.135 
a: Relative standard deviation b: Not more than 
c: Not less than d: Limit of Quantification 
e: Results of all parameters obtain from five replicate injection of standard. f: Intermediate 
Results were verified by measurement of resolution (RS>2.0), % RSD for peak area and retention time (%RSD<2.0), tailing factor (T<2.0), peak 
asymmetry (A<2.0) and theoretical plates (N>4000) from chromatogram of standard solution.  
 
Application of method 
The work presented here is applicable for in-process quality control 
as well as the label claim study and content uniformity test. It is also 
useful for the determination of Tolperisone HCL and Paracetamol as 
a combination dosage form and in individual drug substance form. 
The label claim study carried out using different marketed tablets. 
The individual tablets labeled with Paracetamol, 500 mg (TAMOL, 
Apex Pharmaceuticals Ltd, India) and Tolperisone HCl, 150 mg 
(Tolpidol FC, Themis Medicare Ltd, India) and combination tablet 
(MYO-MR PLUS, Amanath Pharmaceuticals, India) were taken for 
test. The percentage RSD (<2%) and assay (98-102%) of six 
individual injections was measured. The results for both the 
formulations found within the limit. The chromatogram of individual 
marketed formulation preparations are given in fig. 4 (a) and (b) for 
Paracetamol and Tolperisone HCl. 
DISCUSSION 
The reported methods were developed and validated using HPLC 
instrument, whereas proposed research work deals with the column 
packing material with sub 2 µm particle size with a new generation 
instrument UPLC. The importance of the presented method over other 
reported methods includes; stability indicating methods with the shorter 
run-time of both the drugs which elute within 3 minutes. The flow rate is 
very low, thus the consumption of organic solvent is very less. The 
method is also applicable for the individual marketed formulations are 
discussed. The peak purity of both the drugs was checked using a PDA 
detector was found satisfactory and not reported by others. 
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(a) Paracetamol (TAMOL 500 mg, Apex Pharmaceuticals Ltd, India) 
 
(b) Tolperisone HCl (Tolpidol FC 150 mg, Themis Medicare Ltd, India) 
Fig. 4: Chromatographs of individual marked formulations 
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